Back to results
US 2018/0008607 A1Published application
Novel egfr modulators and uses thereof
AssigneeACEA Biosciences, Inc.
InventorsXiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Claims27
A compound of Formula (VIII):
- wherein
- X1 is O, NH, S, CH2, or CF2;
- R1 and R2 are independently selected from hydrogen, halo, C1-6 alkyl, and C1-6 haloalkyl;
- R3 is selected from halo, hydroxyl, C1-6 alkyl, C1-6 alkoxy, cyano, and nitro;
- n is a number from zero to 4;
- R4 is selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, and —NR22R23;
- wherein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino;
- and
- wherein each R22 and R23 are independently selected from hydrogen and C1-6 alkyl or R22 and R23 may be joined to form a 3 to 10 membered ring;
- R5 is selected from hydrogen and C1-6 alkyl;
- R6 is selected from hydrogen, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, hydroxyl, cyano, and nitro;
- R7 is selected from hydrogen, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, hydroxyl, cyano, and nitro;
- R8 is selected from hydrogen, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, hydroxyl, cyano, and nitro;
- Q is CR9 or N;
- R9 is selected from hydrogen, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, hydroxyl, cyano, and nitro;
- R11 is selected from hydrogen and C1-6 alkyl;
- R12 is selected from hydrogen and C1-6 alkyl;
- R13 is selected from hydrogen, C1-6 alkyl, C1-6 acyl, SO2—C1-6alkyl, C3-7 cycloalkyl, and C6-20 aryl,
- wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C1-6 alkoxy, or halo;
- and
- —NR18R19 is
- wherein R10 is selected from hydrogen and C1-6 alkyl;
- R15 is unsubstituted methyl, or is C2-4alkyl unsubstituted or substituted with hydroxy, methoxy, or halo;
- and
- m is 1 or 2;
- or R19 and R9 taken together form a 5- or 6-membered heteroaryl ring optionally substituted with C1-6alkyl that is unsubstituted or substituted with amino, hydroxyl, or halo;
- and R18 is hydrogen or C1-6alkyl, or is absent to satisfy valency of the heteroaryl ring;
- provided that neither of R6 or R7 is methoxy when —NR18R19 is
- or a pharmaceutically acceptable salt thereof.
26 more elements
A compound selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
The compound N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.